AbCellera Biologics Quarterly Income Statements Chart
Quarterly
|
Annual
AbCellera Biologics Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenue: | |||||||||||||||||||
| research fees | 6,639,000 | 4,068,000 | 4,768,000 | 6,289,000 | 5,453,000 | 9,774,000 | 8,744,000 | 6,413,000 | 9,830,000 | 10,570,000 | 11,424,000 | 7,508,000 | 12,538,000 | 9,333,000 | 4,746,000 | 5,128,000 | 5,215,000 | 3,986,000 | |
| licensing revenue | 10,445,000 | 167,000 | 282,000 | 218,000 | 370,000 | 180,000 | 185,000 | 186,000 | 226,000 | 372,000 | 165,000 | 154,000 | 147,000 | 231,000 | 86,000 | 190,000 | 263,000 | 20,259,000 | |
| milestone payments | 1,500,000 | 250,000 | 1,250,000 | 500,000 | 400,000 | 1,000,000 | 7,000,000 | ||||||||||||
| total revenue | 17,084,000 | 4,235,000 | 5,050,000 | 6,507,000 | 7,323,000 | 9,954,000 | 9,179,000 | 6,599,000 | 10,056,000 | 12,192,000 | 21,545,000 | 101,383,000 | 45,917,000 | 316,581,000 | 139,331,000 | 5,508,000 | 27,643,000 | 202,741,000 | |
| yoy | 133.29% | -57.45% | -44.98% | -1.39% | -27.18% | -18.36% | -57.40% | -93.49% | -78.10% | -96.15% | -84.54% | 1740.65% | 66.11% | 56.15% | |||||
| qoq | 303.40% | -16.14% | -22.39% | -11.14% | -26.43% | 8.44% | 39.10% | -34.38% | -17.52% | -43.41% | -78.75% | 120.80% | -85.50% | 127.22% | 2429.61% | -80.07% | -86.37% | ||
| operating expenses: | |||||||||||||||||||
| research and development | 39,213,000 | 42,496,000 | 46,076,000 | 40,969,000 | 40,927,000 | 39,287,000 | 48,622,000 | 37,917,000 | 36,473,000 | 52,647,000 | 28,245,000 | 26,582,000 | 26,685,000 | 26,366,000 | 17,209,000 | 17,450,000 | 15,046,000 | 12,352,000 | |
| sales and marketing | 3,009,000 | 2,842,000 | 3,144,000 | 3,135,000 | 3,136,000 | 3,365,000 | 3,100,000 | 3,468,000 | 3,841,000 | 3,771,000 | 2,691,000 | 3,089,000 | 3,120,000 | 2,370,000 | 1,827,000 | 1,217,000 | 1,295,000 | 2,578,000 | |
| general and administrative | 18,977,000 | 16,226,000 | 16,020,000 | 19,147,000 | 20,192,000 | 17,352,000 | 15,974,000 | 14,369,000 | 15,521,000 | 15,134,000 | 13,015,000 | 13,792,000 | 14,412,000 | 14,268,000 | 12,890,000 | 11,271,000 | 11,203,000 | 6,422,000 | |
| depreciation, amortization, and impairment | 5,470,000 | 12,565,000 | 36,919,000 | 36,522,000 | |||||||||||||||
| total operating expenses | 66,669,000 | 66,895,000 | 77,805,000 | 100,170,000 | 100,777,000 | 64,848,000 | 75,232,000 | 61,489,000 | 61,445,000 | 77,066,000 | 59,323,000 | 63,648,000 | 54,313,000 | 91,631,000 | 57,778,000 | 33,604,000 | 34,676,000 | 44,667,000 | |
| income from operations | -49,585,000 | -62,660,000 | -72,755,000 | -93,663,000 | -93,454,000 | -54,894,000 | -66,053,000 | -54,890,000 | -51,389,000 | -64,874,000 | -37,778,000 | 37,735,000 | -8,396,000 | 224,950,000 | 81,553,000 | -28,096,000 | -7,033,000 | 158,074,000 | |
| yoy | -46.94% | 14.15% | 10.15% | 70.64% | 81.86% | -15.38% | 74.85% | -245.46% | 512.07% | -128.84% | -146.32% | -234.31% | 19.38% | 42.31% | |||||
| qoq | -20.87% | -13.88% | -22.32% | 0.22% | 70.24% | -16.89% | 20.34% | 6.81% | -20.79% | 71.72% | -200.11% | -549.44% | -103.73% | 175.83% | -390.27% | 299.49% | -104.45% | ||
| operating margin % | -290.24% | -1479.57% | -1440.69% | -1439.42% | -1276.17% | -551.48% | -719.61% | -831.79% | -511.03% | -532.10% | -175.34% | 37.22% | -18.29% | 71.06% | 58.53% | -510.09% | -25.44% | 77.97% | |
| other income: | |||||||||||||||||||
| interest income | -7,592,000 | -8,051,000 | -8,668,000 | -9,603,000 | -9,801,000 | -10,401,000 | |||||||||||||
| grants and incentives | -3,692,000 | -4,153,000 | -3,544,000 | -3,491,000 | -3,310,000 | -3,275,000 | -3,376,000 | -2,828,000 | -4,576,000 | -3,374,000 | -1,675,000 | -2,150,000 | -1,535,000 | -5,194,000 | -5,312,000 | -4,380,000 | -4,646,000 | -3,148,000 | |
| other | -1,957,000 | 2,528,000 | 1,529,000 | -3,106,000 | -2,046,000 | 1,970,000 | -3,593,000 | ||||||||||||
| total other income | -13,241,000 | -9,676,000 | -25,926,000 | -31,031,000 | -3,157,000 | -3,124,000 | -4,960,000 | -3,413,000 | |||||||||||
| net income before income tax | -36,344,000 | -52,984,000 | -38,391,500 | -62,632,000 | -48,187,000 | -42,747,000 | |||||||||||||
| income tax recovery | -1,617,000 | -7,363,000 | -6,229,750 | -11,525,000 | -11,257,000 | -2,137,000 | |||||||||||||
| net income | -34,727,000 | -45,621,000 | -32,161,750 | -51,107,000 | -36,930,000 | -40,610,000 | |||||||||||||
| yoy | -5.97% | 12.34% | |||||||||||||||||
| qoq | -23.88% | 41.85% | -37.07% | 38.39% | -9.06% | ||||||||||||||
| net income margin % | -203.27% | -1077.24% | -636.87% | -785.42% | -504.30% | -407.98% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
| foreign currency translation adjustment | 4,341,000 | -2,620,000 | -3,146,000 | 841,000 | -257,000 | -96,000 | -260,000 | 439,000 | 122,000 | -630,000 | -674,000 | -1,293,000 | -211,000 | 507,000 | -364,000 | -1,508,000 | 2,152,000 | ||
| comprehensive loss | -30,386,000 | -48,241,000 | -32,039,750 | -50,266,000 | -37,187,000 | -40,706,000 | |||||||||||||
| net income per share | |||||||||||||||||||
| basic | -0.12 | -0.15 | -0.11 | -0.17 | -0.13 | -0.14 | |||||||||||||
| diluted | -0.12 | -0.15 | -0.11 | -0.17 | -0.13 | -0.14 | |||||||||||||
| weighted-average common shares outstanding | |||||||||||||||||||
| basic | 298,508,601 | 297,692,663 | 294,327,532 | 294,851,945 | 294,217,013 | 292,723,901 | 289,166,486 | 289,496,841 | 288,905,587 | 287,767,136 | 285,056,606 | 285,322,719 | 284,686,542 | 283,895,020 | 275,763,745 | 278,933,760 | 272,196,107 | 269,697,212 | |
| diluted | 298,508,601 | 297,692,663 | 294,327,532 | 294,851,945 | 294,217,013 | 292,723,901 | 289,166,486 | 289,496,841 | 288,905,587 | 287,767,136 | 314,827,255 | 315,818,163 | 284,686,542 | 311,482,017 | 318,294,236 | 278,933,760 | 272,196,107 | 320,282,747 | |
| depreciation and amortization | 5,331,000 | 4,844,000 | 4,214,750 | 5,735,000 | 5,610,000 | 5,514,000 | 3,506,250 | 5,150,000 | 4,886,000 | 3,990,000 | 3,958,000 | 3,666,000 | 3,522,000 | 3,305,000 | |||||
| other income | -12,141,000 | -17,937,000 | -32,156,000 | -1,835,750 | -6,702,000 | 25,000 | -665,000 | 148,750 | 1,256,000 | -314,000 | -265,000 | ||||||||
| total other | -45,267,000 | -12,147,000 | -17,451,000 | -15,614,000 | -13,385,000 | -16,726,000 | -4,055,500 | -8,852,000 | -1,510,000 | -5,859,000 | |||||||||
| royalty revenue | 9,456,000 | 93,321,000 | 33,232,000 | 307,017,000 | 134,499,000 | 190,000 | 21,165,000 | 171,496,000 | |||||||||||
| royalty fees | 1,554,000 | 15,035,000 | 5,210,000 | 44,637,000 | 21,894,000 | 3,610,000 | 20,010,000 | ||||||||||||
| interest | -10,969,000 | -10,740,000 | -10,779,000 | -9,759,000 | |||||||||||||||
| net earnings before income tax | -48,602,000 | -39,276,000 | -38,004,000 | -48,148,000 | -31,412,000 | 46,587,000 | -6,886,000 | 230,809,000 | 84,710,000 | -24,972,000 | -2,073,000 | 161,487,000 | |||||||
| income tax (recovery) expense | -1,452,000 | -10,666,000 | -7,476,000 | -8,038,000 | 20,524,750 | 19,963,000 | -101,000 | ||||||||||||
| net earnings | -47,150,000 | -28,610,000 | -30,528,000 | -40,110,000 | -29,893,000 | 26,624,000 | -6,785,000 | 168,573,000 | 59,948,000 | -21,380,000 | -2,323,000 | ||||||||
| comprehensive income | -47,410,000 | -28,171,000 | -30,406,000 | -40,740,000 | -30,567,000 | 25,331,000 | -6,996,000 | 169,080,000 | 59,584,000 | -22,888,000 | -171,000 | ||||||||
| net earnings per share attributable to common shareholders | |||||||||||||||||||
| basic | -0.17 | -0.1 | -0.11 | -0.14 | -0.1 | 0.09 | -0.02 | 0.59 | 0.22 | -0.08 | -0.01 | 0.43 | |||||||
| diluted | -0.17 | -0.1 | -0.11 | -0.14 | -0.1 | 0.08 | -0.02 | 0.54 | 0.19 | -0.08 | -0.01 | 0.37 | |||||||
| income tax expense | 62,236,000 | ||||||||||||||||||
| income tax | 10,230,750 | -3,592,000 | |||||||||||||||||
| benefit from income tax | 250,000 | 44,266,000 | |||||||||||||||||
| net earnings and comprehensive income for the period | 117,221,000 |
We provide you with 20 years income statements for AbCellera Biologics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of AbCellera Biologics stock. Explore the full financial landscape of AbCellera Biologics stock with our expertly curated income statements.
The information provided in this report about AbCellera Biologics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.